Eagle Pharmaceuticals, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-09-15: Study NCT07325227; Company role Collaborator; Phase Phase 4; Status Not yet recruiting.
- 2023-07-22: Study NCT05776004; Company role Lead sponsor; Phase Phase 2; Status Active not recruiting.
- 2018-08-19: Study NCT03600376; Company role Lead sponsor; Phase Phase 3; Status Completed.
- 2017-11-30: Study NCT03324061; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | NCT07325227 Study of Remimazolam for Cataract Surgery | Collaborator Lead: Fred E, Shapiro | Phase 4 | Not yet recruiting | Cataract Surgery Anesthesia | 30 | 2028-06-01 |
| 2023-07-22 | NCT05776004 Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia | Lead sponsor | Phase 2 | Active not recruiting | Pneumonia, Bacterial | 276 | 2026-09-07 |
| 2018-08-19 | NCT03600376 Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS | Lead sponsor | Phase 3 | Completed Results posted | Exertional Heat Stroke | 17 | 2019-08-14 |
| 2017-11-30 | NCT03324061 Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration | Lead sponsor | Phase 1 | Completed | Pharmacokinetics | 600 | 2018-07-12 |
| 2017-08-12 | NCT03189433 Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT) | Lead sponsor | Phase 2 | Terminated Results posted | Drug Toxicity Psychotropic Agents Psychostimulants | 2 | 2018-12-31 |
| 2015-09 | NCT02513095 Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS) | Lead sponsor | Phase 2 | Completed Results posted | Heat Stroke | 34 | 2015-10 |
| 2013-11 | NCT02162888 A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients | Lead sponsor | Phase 1 | Completed | Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate | 81 | 2014-11 |
| 2008-01 | NCT01045018 A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis | Collaborator Lead: EMET Pharmaceuticals, LLC | Phase 3 | Completed | Mild to Moderate Ulcerative Colitis | 2009-08 |